A Nootropic Ingredient Guide

The word was coined for compounds thought to improve learning while being unusually safe. In a shop it means anything sold with the suggestion that thinking will get easier, and under that umbrella sit three groups that behave nothing like each other.

Stimulants act within an hour and you can feel them. Nutrients act only if you were short of them, and the effect is repair rather than enhancement. Botanicals act over weeks, and their trials are correspondingly long and few.

Sorting each row into one of the three makes a label readable, because the question changes with the group. For a stimulant, how much. For a nutrient, were you short. For a botanical, how long and at what amount of which extract. A fourth group, almost never flagged on a label, is pharmacologically active in the way a medicine is, and it gets a section of its own below.

The place to start is with the reviews that looked at the category as a whole rather than at one ingredient. They are not flattering.

A systematic review of supplement ingredients for cognitive performance in healthy adults set the marketing beside the trials behind it and found the evidence inconsistent, imprecise and often methodologically flawed. A second went through 103 memory supplements sold in United States pharmacies and reached a similar verdict, and NCCIH says much the same in plainer words.

Three things follow, and they shape the rest of this guide. Effect sizes here are small when they exist at all. Trials are often short, small and funded by an ingredient's own maker. And the dose behind a published result is frequently far larger than the dose in a capsule sold on the strength of it.

The useful question is therefore never whether an ingredient has research behind it, because most of them do. It is what that research measured, in whom, for how long, and at what amount.

Thiamine, vitamin B6 and vitamin B12 turn up on most focus labels at several hundred per cent of Daily Value, and the mechanism is real: all three are cofactors in the enzymes that build neurotransmitters. The trials show it only becomes a result if you were running short.

For thiamine, almost the whole cognitive literature runs through deficiency. A 2025 systematic review in alcohol use disorder found lower thiamine tracking with worse attention and memory, and supplementing helped there. In Alzheimer's disease, Cochrane found the evidence insufficient.

For vitamin B12 the pattern is sharper. A meta-analysis of 6,276 participants found no effect on any cognitive subdomain in people who were not deficient, and a separate meta-analysis in community-dwelling older adults found none either. Deficiency is itself treatable, which is why testing beats supplementing blind: it is more common over fifty, on a vegan diet, and on long-term metformin.

Taken as a group, a 2025 meta-analysis put the benefit on global cognition in older adults at very small, and an earlier review of cognitive decline and dementia found no convincing preventive effect. B6 has its own Cochrane review, which found no benefit without deficiency.

B6 is also the one row on a panel of this kind with a ceiling worth knowing. EFSA set the adult tolerable upper intake at 12 mg a day, and the effect deciding that limit is a sensory neuropathy, with a well-described mechanism, reported from ordinary daily multivitamin use. A single product is rarely the problem; a product plus a B-complex plus a fortified drink can be.

All three are methylxanthines or close relatives and all three appear on focus labels. The resemblance ends there: their evidence bases differ by an order of magnitude, and so do their useful doses.

Tyrosine is the amino acid the body converts into dopamine and noradrenaline, which makes the sales pitch obvious and the evidence narrower than the pitch.

The review of this literature concludes that it helps when those transmitters are being depleted by acute stress, cold or sleep loss, and that it is not a general enhancer of thinking in rested, unstressed people. That is a real finding, and it is a much smaller claim than the one on most labels.

The trials that found something matched the situation. Cadets on a combat training course improved on 2 g a day, and working memory held up better during cold exposure at 150 mg per kilogram, around 10 g for a 70 kg adult. A United States military assessment weighed the set and could only make a weak recommendation. A randomised study found the effect on working memory and inhibitory control depended on the participant's dopamine receptor genotype, one reason individual reports disagree so violently.

The practical consequence is arithmetic. Published tyrosine doses are in grams, so a capsule listing tyrosine among several ingredients sharing a few hundred milligrams is not delivering a researched amount of it.

Botanicals are where this category's timing problem lives. Neither reports on day one, and a label implying otherwise is describing the caffeine beside them.

Bacopa monnieri has the best evidence of any botanical here, and its defining feature is duration. The meta-analysis admitted only studies of twelve weeks or longer, and what improved was speed of attention rather than memory. The anchoring trials used 300 mg a day of standardised extract for twelve weeks, and a second twelve-week trial in older adults is in the same range. It is not uniform: a 2025 trial in 101 healthy adults found no benefit over placebo. The recurring adverse effect is stomach upset, which is why it is usually taken with food.

Rhodiola rosea is studied for fatigue and perceived exertion rather than memory. A systematic review of eleven placebo-controlled trials found possible benefits and named the weakness plainly: almost no independent replication. The doses are large, 576 mg a day of standardised extract in the stress-related fatigue trial and 400 mg a day in an open-label burnout study. NCCIH's own page summarises where that leaves it.

For both, the figure to look for is not only the milligrams but the standardisation: an extract with no marker compound named cannot be set beside a trial that used one.

Every other ingredient on this page is a nutrient, a stimulant or a plant extract with a diffuse mechanism. Huperzine-A is a reversible acetylcholinesterase inhibitor: it blocks the enzyme that clears acetylcholine from the synapse, the mechanism class prescription dementia drugs such as donepezil belong to.

It is also active in microgram amounts. Trials use 0.2 to 0.4 mg twice a day, a fraction of a single milligram, and the pharmacokinetic work describes how it behaves there. That has an odd consequence for labels: it is the one ingredient here whose researched dose fits inside almost any blend, which makes it the hardest to rule out and the hardest to quantify.

The efficacy evidence is weaker than its reputation. The best-conducted Western trial found 0.2 mg twice daily did not change the primary cognitive outcome at 16 weeks, Cochrane judged the evidence inadequate for a recommendation, and a later meta-analysis flagged high risk of bias across most trials.

The practical advice is short. If you take a prescribed cholinesterase inhibitor or an anticholinergic medicine, huperzine-A works on the same enzyme system, and that is worth raising with your prescriber first. A label naming huperzine-A without a figure is asking you to take an unknown amount of a pharmacologically active compound.

Every figure here comes from a paper cited above. The third column is the one that matters: set it beside the amount printed on whatever bottle you are holding.

That comparison is usually decisive, and usually in one direction. Botanical and amino acid doses here run to hundreds of milligrams or to grams, and a capsule holding six or seven ingredients rarely has room for one of them at those amounts. Huperzine-A is the systematic exception, so where a long ingredient list sits under one modest total, the ingredient most likely to be there at a researched amount is the one with a pharmacological mechanism and the smallest number beside it.